Physician profile
Kapil Kwatra
NPI 1326016320
$10,357.50
in general payments reported to CMS, 2019-2025
51 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $365 · 2021: $22.73 · 2022: $939 · 2023: $2,512 · 2024: $2,410 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,935 · Education: $55.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,935.02 |
| Education | $55.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,123.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,019.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $885.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $844.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $611.39 | 2022-2025 | |
| Pfizer INC. | $547.88 | 2019-2025 | |
| Amgen INC. | $453.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $425.60 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $421.14 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $367.19 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $357.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.88 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $279.10 | 2022-2025 | Rexulti |
| Lundbeck LLC | $232.56 | 2023-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.22 | 2019-2025 | Jardiance, Synjardy |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kapil Kwatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.